Sensei Biotherapeutics Reports Significant Q1 Losses Amid Pipeline Developments
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 19 2026
0mins
Source: NASDAQ.COM
- Escalating Financial Losses: Sensei Biotherapeutics reported a net loss of $170.24 million for Q1 2026, translating to $131.45 per share, nearly doubling from a loss of $6.9 million or $5.45 per share in the same quarter last year, primarily driven by $133 million in IPR&D expenses from the acquisition of Faeth Therapeutics.
- Surge in R&D Expenses: R&D expenses reached $17.95 million in Q1 2026, a significant increase from $3.72 million in 2025, indicating the company's ongoing commitment to drug development despite the short-term financial strain.
- Cash Reserves Status: As of March 31, 2026, Sensei held $202.8 million in cash, cash equivalents, and marketable securities, providing sufficient liquidity to support ongoing research activities despite the increased losses.
- Clinical Trial Progress: The company is conducting a Phase 1b/2 trial for PIKTOR targeting HR+/HER2- advanced breast cancer, with the first patient dosed in April and interim data expected in 2027, showcasing the company's potential in cancer treatment.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SNSE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SNSE
About SNSE
Sensei Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients. The Company's lead program is PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer. The Company is also completing a Phase I/II trial of solnerstotug, its V-domain Ig suppressor of T cell activation (VISTA) inhibitor, in patients with advanced solid tumors. Its TMAb platform is designed to enable highly selective targeting through conditional antibody activation of immune cells in the tumor microenvironment without on-target, off-tumor activity. Its programs include Solnerstotug (SNS-101), SNS-102, SNS-103, and SNS-201. Solnerstotug is a conditionally active, human monoclonal IgG1 antibody designed to block the VISTA checkpoint, which acts as a suppressor of T cells by binding the receptor PSGL-1.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sensei Biotherapeutics Reports Significant Q1 Losses Amid Pipeline Developments
- Escalating Financial Losses: Sensei Biotherapeutics reported a net loss of $170.24 million for Q1 2026, translating to $131.45 per share, nearly doubling from a loss of $6.9 million or $5.45 per share in the same quarter last year, primarily driven by $133 million in IPR&D expenses from the acquisition of Faeth Therapeutics.
- Surge in R&D Expenses: R&D expenses reached $17.95 million in Q1 2026, a significant increase from $3.72 million in 2025, indicating the company's ongoing commitment to drug development despite the short-term financial strain.
- Cash Reserves Status: As of March 31, 2026, Sensei held $202.8 million in cash, cash equivalents, and marketable securities, providing sufficient liquidity to support ongoing research activities despite the increased losses.
- Clinical Trial Progress: The company is conducting a Phase 1b/2 trial for PIKTOR targeting HR+/HER2- advanced breast cancer, with the first patient dosed in April and interim data expected in 2027, showcasing the company's potential in cancer treatment.
See More
Sensei Biotherapeutics Reports Q1 2026 Financial Results and Clinical Updates
- Clinical Trial Progress: In April 2026, Sensei Biotherapeutics dosed the first patient in its Phase 1b/2 trial for HR+/HER2- advanced breast cancer, with interim data expected in 2027, marking a significant advancement in the company's oncology pipeline.
- Financial Position Change: As of March 31, 2026, the company reported cash and cash equivalents of $202.8 million, a substantial increase from $21.2 million as of December 31, 2025, reflecting the positive impact of the capital infusion from the acquisition of Faeth Therapeutics on the company's financial health.
- Surge in R&D Expenses: Research and development expenses for Q1 2026 reached $18 million, a dramatic rise from $3.7 million in Q1 2025, primarily due to the inclusion of Faeth's R&D operations and one-time costs associated with the acquisition, indicating the company's ongoing commitment to drug development.
- Widening Net Loss: The net loss for Q1 2026 was $170.2 million, or $131.45 per share, significantly higher than the $6.9 million loss and $5.45 per share loss reported in Q1 2025, highlighting the financial pressures faced by the company as it expands its R&D and market presence.
See More
GT Biopharma Initiates Phase 1 Trial of GTB-5550 for Solid Tumors
- Trial Launch: On May 14, 2026, GT Biopharma announced that the first patient has been dosed in the Phase 1 trial of GTB-5550, a B7-H3-targeted natural killer cell engager, marking a significant advancement in treating historically resistant solid tumors.
- Innovative Dosing Method: GTB-5550 is the first TriKE® molecule tested with subcutaneous dosing, administered for five consecutive days in the abdominal area during each four-week cycle, which is expected to enhance patient compliance and reduce treatment-related side effects.
- Broad Tumor Type Coverage: The trial is designed as a basket study encompassing seven solid tumor types, including prostate, ovarian, breast, head and neck, non-small cell lung, pancreatic, and bladder cancers, indicating the potential applicability of GTB-5550 across multiple difficult-to-treat tumors.
- Strong Market Demand: With prostate and pancreatic cancers historically unresponsive to standard immunotherapies, GTB-5550 is poised to address this significant unmet medical need, enhancing the company's competitiveness in the rapidly evolving immuno-oncology market.
See More
Sensei Biotherapeutics Launches PIKTOR Clinical Trial for Advanced Breast Cancer
- Trial Launch: Sensei Biotherapeutics has initiated the Phase 1b/2 trial FTH-PIK-101 for PIKTOR in HR+/HER2- advanced breast cancer patients, marking a significant advancement in cancer treatment.
- Multi-Node Inhibition: PIKTOR combines serabelisib and sapanisertib to inhibit multiple nodes of the PI3K/AKT/mTOR pathway, offering a more effective treatment option compared to single-node inhibitors, particularly for tumors in approximately 50% of HR+/HER2- patients.
- Early Study Results: In a prior Phase 1b study, PIKTOR combined with paclitaxel demonstrated a 47% overall response rate, with a notable 71% response rate among patients with PI3K pathway mutations, highlighting its potential clinical value.
- Strategic Development: The launch of this clinical trial not only enhances Sensei's competitiveness in the biotechnology sector but also lays the groundwork for its future clinical development plans, especially in the ongoing FTH-PIK-201 study targeting advanced endometrial cancer.
See More
SENSEI Biotherapeutics Administers First Dose to Patient in Phase 1B/2 Trial of PIKTOR for HR+/HER2- Advanced Breast Cancer
First Patient Dosed: Sensei Biotherapeutics has successfully dosed the first patient in Phase 1/2 clinical trial of Piktor, a treatment for HR+/HER2- advanced breast cancer.
Trial Objectives: The trial aims to evaluate the safety, tolerability, and preliminary efficacy of Piktor in patients with this specific type of breast cancer.
Significance of the Treatment: Piktor is designed to target and potentially improve outcomes for patients with HR+/HER2- advanced breast cancer, a common and challenging subtype of the disease.
Future Implications: The progress of this trial could pave the way for new therapeutic options in the treatment landscape for advanced breast cancer patients.
See More
Surge in Short Selling of Small-Cap Healthcare Stocks
- Surge in Short Interest: As of the end of April, small-cap healthcare stocks have seen a significant increase in short interest, with Sensei Biotherapeutics at 63.85%, indicating strong investor concerns over clinical outcomes and balance sheet health, which could lead to further price declines.
- Market Performance Contrast: Despite a 5.62% year-to-date rally in the S&P 500, the Health Care Select Sector SPDR® Fund (XLV) has declined by 6.23%, reflecting the sector's weak performance in 2026, which may impact investor confidence.
- Most Shorted Stocks: As of April 30, KalVista Pharmaceuticals and GlucoTrack have short interests of 38.35% and 34.48%, respectively, indicating significant market pressure on these biotech firms, potentially affecting their financing and operational capabilities.
- Least Shorted Stocks: Beyond Air and Polaryx Therapeutics have short interests of only 0.50%, demonstrating relative stability in the market, which may attract investors looking for lower-risk opportunities.
See More
Sensei Biotherapeutics Reports Significant Q1 Losses Amid Pipeline Developments
- Escalating Financial Losses: Sensei Biotherapeutics reported a net loss of $170.24 million for Q1 2026, translating to $131.45 per share, nearly doubling from a loss of $6.9 million or $5.45 per share in the same quarter last year, primarily driven by $133 million in IPR&D expenses from the acquisition of Faeth Therapeutics.
- Surge in R&D Expenses: R&D expenses reached $17.95 million in Q1 2026, a significant increase from $3.72 million in 2025, indicating the company's ongoing commitment to drug development despite the short-term financial strain.
- Cash Reserves Status: As of March 31, 2026, Sensei held $202.8 million in cash, cash equivalents, and marketable securities, providing sufficient liquidity to support ongoing research activities despite the increased losses.
- Clinical Trial Progress: The company is conducting a Phase 1b/2 trial for PIKTOR targeting HR+/HER2- advanced breast cancer, with the first patient dosed in April and interim data expected in 2027, showcasing the company's potential in cancer treatment.
See More
Sensei Biotherapeutics Reports Q1 2026 Financial Results and Clinical Updates
- Clinical Trial Progress: In April 2026, Sensei Biotherapeutics dosed the first patient in its Phase 1b/2 trial for HR+/HER2- advanced breast cancer, with interim data expected in 2027, marking a significant advancement in the company's oncology pipeline.
- Financial Position Change: As of March 31, 2026, the company reported cash and cash equivalents of $202.8 million, a substantial increase from $21.2 million as of December 31, 2025, reflecting the positive impact of the capital infusion from the acquisition of Faeth Therapeutics on the company's financial health.
- Surge in R&D Expenses: Research and development expenses for Q1 2026 reached $18 million, a dramatic rise from $3.7 million in Q1 2025, primarily due to the inclusion of Faeth's R&D operations and one-time costs associated with the acquisition, indicating the company's ongoing commitment to drug development.
- Widening Net Loss: The net loss for Q1 2026 was $170.2 million, or $131.45 per share, significantly higher than the $6.9 million loss and $5.45 per share loss reported in Q1 2025, highlighting the financial pressures faced by the company as it expands its R&D and market presence.
See More
GT Biopharma Initiates Phase 1 Trial of GTB-5550 for Solid Tumors
- Trial Launch: On May 14, 2026, GT Biopharma announced that the first patient has been dosed in the Phase 1 trial of GTB-5550, a B7-H3-targeted natural killer cell engager, marking a significant advancement in treating historically resistant solid tumors.
- Innovative Dosing Method: GTB-5550 is the first TriKE® molecule tested with subcutaneous dosing, administered for five consecutive days in the abdominal area during each four-week cycle, which is expected to enhance patient compliance and reduce treatment-related side effects.
- Broad Tumor Type Coverage: The trial is designed as a basket study encompassing seven solid tumor types, including prostate, ovarian, breast, head and neck, non-small cell lung, pancreatic, and bladder cancers, indicating the potential applicability of GTB-5550 across multiple difficult-to-treat tumors.
- Strong Market Demand: With prostate and pancreatic cancers historically unresponsive to standard immunotherapies, GTB-5550 is poised to address this significant unmet medical need, enhancing the company's competitiveness in the rapidly evolving immuno-oncology market.
See More
Sensei Biotherapeutics Launches PIKTOR Clinical Trial for Advanced Breast Cancer
- Trial Launch: Sensei Biotherapeutics has initiated the Phase 1b/2 trial FTH-PIK-101 for PIKTOR in HR+/HER2- advanced breast cancer patients, marking a significant advancement in cancer treatment.
- Multi-Node Inhibition: PIKTOR combines serabelisib and sapanisertib to inhibit multiple nodes of the PI3K/AKT/mTOR pathway, offering a more effective treatment option compared to single-node inhibitors, particularly for tumors in approximately 50% of HR+/HER2- patients.
- Early Study Results: In a prior Phase 1b study, PIKTOR combined with paclitaxel demonstrated a 47% overall response rate, with a notable 71% response rate among patients with PI3K pathway mutations, highlighting its potential clinical value.
- Strategic Development: The launch of this clinical trial not only enhances Sensei's competitiveness in the biotechnology sector but also lays the groundwork for its future clinical development plans, especially in the ongoing FTH-PIK-201 study targeting advanced endometrial cancer.
See More
SENSEI Biotherapeutics Administers First Dose to Patient in Phase 1B/2 Trial of PIKTOR for HR+/HER2- Advanced Breast Cancer
First Patient Dosed: Sensei Biotherapeutics has successfully dosed the first patient in Phase 1/2 clinical trial of Piktor, a treatment for HR+/HER2- advanced breast cancer.
Trial Objectives: The trial aims to evaluate the safety, tolerability, and preliminary efficacy of Piktor in patients with this specific type of breast cancer.
Significance of the Treatment: Piktor is designed to target and potentially improve outcomes for patients with HR+/HER2- advanced breast cancer, a common and challenging subtype of the disease.
Future Implications: The progress of this trial could pave the way for new therapeutic options in the treatment landscape for advanced breast cancer patients.
See More
Surge in Short Selling of Small-Cap Healthcare Stocks
- Surge in Short Interest: As of the end of April, small-cap healthcare stocks have seen a significant increase in short interest, with Sensei Biotherapeutics at 63.85%, indicating strong investor concerns over clinical outcomes and balance sheet health, which could lead to further price declines.
- Market Performance Contrast: Despite a 5.62% year-to-date rally in the S&P 500, the Health Care Select Sector SPDR® Fund (XLV) has declined by 6.23%, reflecting the sector's weak performance in 2026, which may impact investor confidence.
- Most Shorted Stocks: As of April 30, KalVista Pharmaceuticals and GlucoTrack have short interests of 38.35% and 34.48%, respectively, indicating significant market pressure on these biotech firms, potentially affecting their financing and operational capabilities.
- Least Shorted Stocks: Beyond Air and Polaryx Therapeutics have short interests of only 0.50%, demonstrating relative stability in the market, which may attract investors looking for lower-risk opportunities.
See More
